A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes—a finding that could guide treatment ...

Testing a key lymph node in patients with the most dangerous form of skin cancer is the best approach to determine if the cancer has spread, new late-stage clinical research indicates. The test could ...

For years, surgeons have operated on pancreatic cancer patients to remove what they thought was a localized tumor only to discover that the disease had spread to other, inoperable parts of the body.

Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to ...

Scientists at City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, have developed a novel, noninvasive liquid biopsy test for detecting lymph node ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today ...

SAN ANTONIO, Dec. 18 /PRNewswire/ -- Results from a prospective clinical study show that the GeneSearch(TM) Breast Lymph Node (BLN) Assay, a gene-based diagnostic test has greater sensitivity than ...

SLNB surgery is used to determine whether a patient’s melanoma has spread to the lymph node; the procedure has the potential for complications and returns a biopsy that is negative for metastatic ...

Please provide your email address to receive an email when new articles are posted on . Up to 88% of sentinel lymph node biopsies (SNLB) return with a negative result. The DecisionDx-Melanoma test, ...

Lymph node dissections, or lymphadenectomies, are surgical procedures that play an important role in cancer treatments. A healthcare professional will remove the lymph nodes and check a tissue sample ...